[1]Patent:US2009/274652,2009,A1,.Locationinpatent:Page/Pagecolumn38;40
[1]BioorganicandMedicinalChemistryLetters,2011,vol.21,#7,p.2048-2054
[1]Patent:WO2012/166459,2012,A1,.Locationinpatent:Page/Pagecolumn29
[1]Patent:WO2009/85659,2009,A1,.Locationinpatent:Page/Pagecolumn25;26-27
[1]JournalofMedicinalChemistry,2014,vol.57,#5,p.1730-1752
[1]Patent:WO2009/85659,2009,A1.Locationinpatent:Page/Pagecolumn25;26-27
[1]Patent:US2009/274652,2009,A1.Locationinpatent:Page/Pagecolumn38-40
62965-35-9
630420-16-5
[1]Patent:US2009/274652,2009,A1.Locationinpatent:Page/Pagecolumn38;40
[1]BioorganicandMedicinalChemistryLetters,2011,vol.21,p.2048-2054
Title: The discovery of asunaprevir (BMS-650032), an orally efficacious NS3 protease inhibitor for the treatment of hepatitis C virus infection.
Journal: Journal of medicinal chemistry 20140313
Title: Highly efficient infectious cell culture of three hepatitis C virus genotype 2b strains and sensitivity to lead protease, nonstructural protein 5A, and polymerase inhibitors.
Journal: Hepatology (Baltimore, Md.) 20140201
Title: Combination treatment with hepatitis C virus protease and NS5A inhibitors is effective against recombinant genotype 1a, 2a, and 3a viruses.
Journal: Antimicrobial agents and chemotherapy 20130301
Title: Combinations of lambda interferon with direct-acting antiviral agents are highly efficient in suppressing hepatitis C virus replication.
Journal: Antimicrobial agents and chemotherapy 20130301
Title: Pelosi LA, et al. Effect on HCV Replication by Combinations of Direct Acting Antivirals Including NS5A Inhibitor BMS-790052.Antimicrob Agents Chemother. 2012 Jul 30.
Title: McPhee F, et al. Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032).Antimicrob Agents Chemother. 2012 Aug 6.
Title: McPhee F, et al. Resistance analysis of the hepatitis C virus NS3 protease inhibitor asunaprevir. Antimicrob Agents Chemother. 2012 Jul;56(7):3670-81.
Title: Pasquinelli C, et al. Single- and multiple-ascending-dose studies of the NS3 protease inhibitor asunaprevir in subjects with or without chronic hepatitis C. Antimicrob Agents Chemother. 2012 Apr;56(4):1838-44.
Title: Qi Sun, et al. Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease. Signal Transduct Target Ther. 2021 May 29;6(1):212.
